Natco Pharma

Corporate brand

Natco Pharma is an Indian pharmaceutical company focused on complex generics, oncology, specialty medicines, active pharmaceutical ingredients, finished dosage formulations, and selected agrochemical products.

Last updated October 14, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Natco Pharma is an Indian multinational pharmaceutical company headquartered in Hyderabad. Founded by V. C. Nannapaneni in 1981, it developed from a domestic manufacturing business into a research-oriented pharmaceutical group with activities spanning finished dosage formulations, active pharmaceutical ingredients, specialty medicines, and agrochemicals. Its operating model has emphasized products that are technically difficult to manufacture, commercially important, or underserved by conventional pharmaceutical competition. The company began operations at a manufacturing facility in Nagarjunasagar in 1983. In 1986, it established a chemical division at Mekaguda near Hyderabad, strengthening its ability to produce pharmaceutical ingredients and support formulation development. Over time, Natco became particularly associated with oncology products and other specialty therapies, while also building activities in cardiology, diabetology, and additional therapeutic areas. The company’s stated market proposition has generally combined technical capability with access-oriented pricing, especially in areas where branded medicines may be expensive or where generic competition is limited. Natco’s international strategy has included regulatory filings, licensing, and partnerships rather than relying exclusively on wholly owned commercial operations. It made its first Paragraph IV filing in the United States in 2008, a step that reflected a focus on challenging pharmaceutical patents and pursuing earlier entry for generic medicines where legally and technically possible. The company subsequently participated in the U.S. launches of products including oseltamivir, marketed as Tamiflu, in partnership with Alvogen; glatiramer acetate with Mylan; and hepatitis C medicines under a licensing arrangement with Gilead Sciences. These collaborations gave Natco access to international commercialization networks while allowing it to contribute manufacturing, development, or regulatory capabilities. A major turning point came in 2012, when Natco received an Indian compulsory licence to manufacture and sell a lower-priced generic version of Bayer’s cancer medicine Nexavar, whose active ingredient is sorafenib. The decision made Natco prominent in debates over pharmaceutical patents, public-health access, and the balance between innovation incentives and affordability. Oncology has remained a central part of the company’s identity, and Natco has also introduced or supplied products for blood cancers and other serious diseases. In the United States, Natco launched the first Tamiflu capsule in 2016 and introduced a generic version of the blood-cancer medicine pomalidomide in 2017. These launches reinforced its position in complex and specialty generics. Beyond pharmaceuticals, the company began work in 2019 on greenfield manufacturing facilities for niche agrochemical products in Nellore district, Andhra Pradesh, reflecting an effort to diversify its manufacturing and product base. Natco expanded its corporate reach in 2025 by completing the acquisition of a 35.75% stake in Adcock Ingram, a South African pharmaceutical company. The transaction was reported at approximately US$226 million and resulted in Adcock Ingram’s delisting from the Johannesburg Stock Exchange. The investment connected Natco more closely with a major African healthcare market and broadened its strategic footprint beyond its established Indian and U.S.-linked activities. Today, Natco Pharma is best understood as a specialty and complex-generics pharmaceutical group rather than a consumer-facing medicine brand. Its portfolio and partnerships are concentrated in areas requiring regulatory expertise, specialized manufacturing, intellectual-property strategy, or reliable supply of important therapies. Publicly available reference material supports its role in oncology, specialty pharmaceuticals, APIs, finished dosages, and agrochemicals; a complete current product catalogue, executive roster, and financial profile would require verification from company filings and regulatory sources.

History

Natco Pharma was established in India in 1981 by V. C. Nannapaneni. Its early development centered on building domestic pharmaceutical manufacturing capacity. Operations began at Nagarjunasagar in 1983, and the company added a chemical division at Mekaguda near Hyderabad in 1986. The latter development helped establish a foundation for active pharmaceutical ingredient production and chemical capabilities alongside finished-dose manufacturing. As the business matured, Natco concentrated on specialty and technically demanding medicines. Oncology became one of its most visible areas, complemented by products in cardiology, diabetology, and other therapeutic fields. Rather than competing only through broad commodity-generic volumes, the company pursued products where development, manufacturing, regulatory approval, or intellectual-property work could create a more defensible position. Its portfolio came to include finished formulations, APIs, and later selected agrochemical products. Natco entered the U.S. patent-challenge pathway in 2008 with its first Paragraph IV filing. This approach is used by generic-drug manufacturers seeking approval for products while asserting that relevant patents are invalid, unenforceable, or not infringed. It became an important element of Natco’s international strategy and supported later partnerships for U.S. commercialization. In 2012, Natco obtained an Indian compulsory licence to produce a cheaper generic version of Bayer’s Nexavar, an oncology medicine containing sorafenib. The licence was a landmark event in Indian pharmaceutical and patent-policy history. It highlighted Natco’s access-oriented positioning while also placing the company at the center of an industry dispute concerning pricing, patent protection, and the public-health responsibilities of rights holders. Natco subsequently expanded its international product activities through commercial and licensing relationships. In the United States, it launched oseltamivir, the generic form of the influenza medicine Tamiflu, with Alvogen. It also worked with Mylan on glatiramer acetate for multiple sclerosis and supplied or developed hepatitis C medicines under a licensing arrangement with Gilead Sciences. In 2016, Natco launched the first Tamiflu capsule in the U.S. market. In 2017, it launched a generic version of pomalidomide, a blood-cancer medicine, in the United States. The company also pursued diversification outside human pharmaceuticals. In 2019, it started work on greenfield manufacturing facilities for niche agrochemical products in Nellore district, Andhra Pradesh. This initiative extended Natco’s manufacturing and product-development capabilities into agricultural chemicals while retaining a focus on specialized products rather than undifferentiated mass-market output. In 2025, Natco completed the purchase of a 35.75% stake in Adcock Ingram, a South African pharmaceutical company. The transaction, reported at approximately US$226 million, resulted in Adcock Ingram’s delisting from the Johannesburg Stock Exchange. The investment represented a significant step in Natco’s international corporate expansion and increased its connection with pharmaceutical distribution and commercial activity in South Africa. Natco Pharma’s historical identity therefore rests on three connected themes: Indian manufacturing depth, specialization in complex and high-need medicines, and the use of regulatory, licensing, and partnership strategies to reach international markets. Its best-known public milestones concern affordable oncology treatment, U.S. generic launches, and the extension of its capabilities into agrochemicals and overseas corporate investment.

2025
Adcock Ingram stake acquisition completed
[1]Natco Pharmaen.wikipedia.org
Natco completed the acquisition of a 35.75% stake in South Africa’s Adcock Ingram, followed by the company’s delisting from the Johannesburg Stock Exchange.
2019
Nellore agrochemical facilities initiated
[1]Natco Pharmaen.wikipedia.org
The company began work on greenfield facilities for niche agrochemical products in Andhra Pradesh.
2017
U.S. generic pomalidomide launch
[1]Natco Pharmaen.wikipedia.org
Natco launched a generic version of pomalidomide in the United States.
2016
U.S. Tamiflu capsule launch
[1]Natco Pharmaen.wikipedia.org
Natco launched an oseltamivir capsule in the United States with Alvogen.
2012
Compulsory licence for generic Nexavar
[1]Natco Pharmaen.wikipedia.org
Natco obtained an Indian compulsory licence to produce a lower-priced generic version of Bayer’s Nexavar.
2008
First U.S. Paragraph IV filing
[1]Natco Pharmaen.wikipedia.org
Natco filed its first Paragraph IV application in the United States.
1986
Chemical division established at Mekaguda
[1]Natco Pharmaen.wikipedia.org
Natco began chemical-division operations at Mekaguda near Hyderabad.
1983
Manufacturing operations begin at Nagarjunasagar
[1]Natco Pharmaen.wikipedia.org
The company commenced operations at a manufacturing facility in Nagarjunasagar.
1981
Natco Pharma founded
[1]Natco Pharmaen.wikipedia.org
V. C. Nannapaneni founded Natco Pharma in India.

Products and positioning

An Indian specialty-pharmaceutical and complex-generics company emphasizing affordable access, oncology and other high-need therapies, specialized manufacturing, regulatory capability, and selected international partnerships.

Oncology medicine · 2012
Sorafenib generic
Natco’s generic sorafenib became closely associated with the 2012 Indian compulsory-licence decision involving Bayer’s Nexavar. The product represented the company’s emphasis on improving access to costly cancer therapies and demonstrated its ability to manufacture and seek regulatory authorization for a complex oncology medicine. The case also made Natco a prominent example in discussions about Indian patent law and public-health licensing.
Antiviral medicine · 2016
Oseltamivir capsules
Natco supplied an oseltamivir capsule for the U.S. market in partnership with Alvogen. Oseltamivir is used against influenza, and the U.S. launch broadened Natco’s international generic portfolio beyond oncology. The reference material identifies the product as a generic form of Tamiflu and records the first capsule launch in the U.S. market in 2016.
Multiple-sclerosis medicine
Glatiramer acetate
Glatiramer acetate is a multiple-sclerosis treatment that Natco launched or supplied internationally through a partnership with Mylan. The collaboration illustrates Natco’s use of established commercial partners to reach regulated overseas markets while contributing pharmaceutical development and manufacturing capabilities.
Antiviral medicines
Hepatitis C medicines
Natco participated in hepatitis C medicines under a licensing arrangement with Gilead Sciences. The arrangement formed part of the company’s international specialty-medicine activities and connected its manufacturing and access-oriented capabilities with Gilead’s licensing framework. Specific product names and launch dates are not established in the supplied material.
Hematology and oncology medicine · 2017
Pomalidomide generic
Natco launched a generic version of pomalidomide in the United States in 2017. Pomalidomide is used in blood-cancer treatment, making the launch consistent with Natco’s focus on oncology and hematology products that require specialized regulatory and manufacturing capabilities.
Agrochemicals · 2019
Agrochemical products
Natco began developing greenfield manufacturing facilities in Nellore district, Andhra Pradesh, for niche agrochemical products in 2019. The initiative represents diversification from human medicines into agricultural chemicals. The supplied sources do not identify a complete product list or specific commercial launch dates.

Brand decisions

2025
Acquisition of a strategic stake in Adcock IngramM&A
Background
Natco pursued international expansion through an investment in Adcock Ingram, a South African pharmaceutical company.
Action taken
Natco completed the acquisition of a 35.75% stake in Adcock Ingram for approximately US$226 million.
Aftermath
Adcock Ingram was delisted from the Johannesburg Stock Exchange, and Natco gained a larger strategic connection to the South African pharmaceutical market.
Transaction value. Approximately US$226 million (2025)
Source
2019
Expansion into niche agrochemical manufacturingStrategy
Background
Natco sought to diversify its manufacturing and product base beyond human pharmaceuticals while retaining a focus on specialized products.
Action taken
The company initiated work on greenfield manufacturing facilities for niche agrochemical products in Nellore district, Andhra Pradesh.
Aftermath
The initiative broadened Natco’s industrial scope, although the supplied material does not provide later capacity, product, or revenue details.
Source
2012
Pursuit and receipt of compulsory licence for generic NexavarOther
Background
Natco sought authorization to manufacture a lower-priced version of Bayer’s cancer medicine Nexavar in India. The matter addressed access to an expensive oncology treatment and became a major test of the country’s compulsory-licensing framework.
Action taken
Indian authorities granted Natco a compulsory licence to produce and sell the generic medicine, subject to the terms of the licence.
Aftermath
The decision strengthened Natco’s public profile as an access-oriented oncology manufacturer and generated wider debate over pharmaceutical patents, pricing, and public health.
Source

Recent events

2025
Natco completes acquisition of stake in Adcock Ingram[1]Natco Pharmaen.wikipedia.org
M&A
Natco Pharma completed the acquisition of a 35.75% holding in South African pharmaceutical company Adcock Ingram. The transaction was reported at approximately US$226 million and was followed by Adcock Ingram’s delisting from the Johannesburg Stock Exchange.
2019
Natco begins greenfield agrochemical manufacturing development[1]Natco Pharmaen.wikipedia.org
Product launch
Natco initiated work on new manufacturing facilities in Nellore district, Andhra Pradesh, for niche agrochemical products.
2017
Natco launches generic pomalidomide in the United States[1]Natco Pharmaen.wikipedia.org
Product launch
The company launched a generic version of pomalidomide, a medicine used in blood-cancer treatment, in the United States.
2016
Natco Pharma launches Tamiflu capsule in the United States[1]Natco Pharmaen.wikipedia.org
Product launch
Natco launched an oseltamivir capsule in the U.S. market with Alvogen as its marketing partner, expanding its role in international generic-drug supply.
2012
Natco Pharma receives compulsory licence for generic Nexavar[1]Natco Pharmaen.wikipedia.org
Regulation · Other
India granted Natco Pharma a compulsory licence to manufacture and sell a lower-priced generic version of Bayer’s oncology medicine Nexavar, making the company a prominent participant in international debate over patent rights and medicine affordability.

Sources12 sources

Cite this profile: Cite the canonical profile. /brand-wiki/natco-pharma · Editorial policy · How profiles are compiled